Placebo responses in genetically determined intellectual disability: A meta-analysis

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Curie, Aurore ^a,b,c,d,e   Yang, Kathy ^a   Kirsch, Irving ^f,g   Gollub, Randy L ^a   Des Portes, Vincent ^b,c,d   Kaptchuk, Ted J ^f   Jensen, Karin B ^a,f,h  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b INSTITUT DES SCIENCES COGNITIVES   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d UNIVERSITÉ LYON 1   (France)

^e Inserm   (France)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g UNIVERSITY OF PLYMOUTH   (United Kingdom)

^h KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; GROWTH HORMONE; LEVACECARNINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PLACEBO; TETRACYCLINE; THYROXINE; VITAMIN;

AGE DISTRIBUTION; ARTICLE; ATTENTION; COMORBIDITY; DATA EXTRACTION; DATA SYNTHESIS; DEMENTIA; DRUG RESPONSE; EFFECT SIZE; GENETICALLY DETERMINED INTELLECTUAL DISABILITY; HUMAN; IMPLICIT LEARNING; INTELLECTUAL IMPAIRMENT; INTELLIGENCE QUOTIENT; LANGUAGE; LEARNING; MEMORY; META ANALYSIS; MIXED EFFECT MODEL; NONBIOLOGICAL MODEL; OBJECTIVE OUTCOME; OUTCOME ASSESSMENT; PLACEBO EFFECT; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUBJECTIVE OUTCOME; TREATMENT DURATION; TREATMENT OUTCOME; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; GENETICS; INTELLECTUAL DISABILITY; MALE; MENTAL FUNCTION; PSYCHOLOGY;

DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTELLECTUAL DISABILITY; MALE; MENTAL PROCESSES; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84942163067     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0133316     Document Type: Article

References (84)

1. Association AP. Diagnostic and statistical manual of mental disorders: DSM-5 ( 5th ed.). Arlington, VA: American Psychiatric Publishing, Inc 2013.
2. Teipel SJ, Hampel H. Neuroanatomy of Down syndrome in vivo: a model of preclinical Alzheimer's disease. Behav Genet. 2006; 36(3):405-15. doi: 10.1007/s10519-006-9047-x PMID: 16485178.
3. Picker JD, Walsh CA. New innovations: therapeutic opportunities for intellectual disabilities. Ann Neurol. 2013; 74(3):382-90. doi: 10.1002/ana.24002 PMID: 24038210; PubMed Central PMCID: PMC3876407.
4. Buchel C, Geuter S, Sprenger C, Eippert F. Placebo analgesia: a predictive coding perspective. Neuron. 2014; 81(6):1223-39. doi: 10.1016/j.neuron.2014.02.042 PMID: 24656247.
5. Waber RL, Shiv B, Carmon Z, Ariely D. Commercial features of placebo and therapeutic efficacy. JAMA. 2008; 299(9):1016-7. doi: 10.1001/jama.299.9.1016 PMID: 18319411.
6. Kaptchuk TJ, Kelley JM, Conboy LA, Davis RB, Kerr CE, Jacobson EE, et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ. 2008; 336 (7651):999-1003. doi: 10.1136/bmj.39524.439618.25 PMID: 18390493
7. Colloca L, Sigaudo M, Benedetti F. The role of learning in nocebo and placebo effects. Pain. 2008; 136 (1-2):211-8. doi: 10.1016/j.pain.2008.02.006 PMID: 18372113.
8. Allan LG, Siegel S. A signal detection theory analysis of the placebo effect. Eval Health Prof. 2002; 25 (4):410-20. PMID: 12449084.
9. Enck P, Bingel U, Schedlowski M, Rief W. The placebo response in medicine: minimize, maximize or personalize? Nat Rev Drug Discov. 2013; 12(3):191-204. doi: 10.1038/nrd3923 PMID: 23449306.
10. de la Fuente-Fernandez R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science. 2001; 293 (5532):1164-6. doi: 10.1126/science.1060937 PMID: 11498597.
11. Benedetti F, Colloca L, Torre E, Lanotte M, Melcarne A, Pesare M, et al. Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus. Nat Neurosci. 2004; 7 (6):587-8. doi: 10.1038/nn1250 PMID: 15146189.
12. Eippert F, Bingel U, Schoell ED, Yacubian J, Klinger R, Lorenz J, et al. Activation of the opioidergic descending pain control system underlies placebo analgesia. Neuron. 2009; 63(4):533-43. doi: 10. 1016/j.neuron.2009.07.014 PMID: 19709634.
13. Petrovic P, Kalso E, Petersson KM, Ingvar M. Placebo and opioid analgesia - imaging a shared neuronal network. Science. 2002; 295(5560):1737-40. doi: 10.1126/science.1067176 PMID: 11834781.
14. Wager TD, Rilling JK, Smith EE, Sokolik A, Casey KL, Davidson RJ, et al. Placebo-Induced Changes in fMRI in the Anticipation and Experience of Pain. Science. 2004; 303(5661):1162-7. doi: 10.1126/science.1093065 PMID: 14976306
15. Zubieta JK, Bueller JA, Jackson LR, Scott DJ, Xu Y, Koeppe RA, et al. Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. J Neurosci. 2005; 25(34):7754-62. doi: 10.1523/JNEUROSCI.0439-05.2005 PMID: 16120776.
16. Leuchter AF, Cook IA, Witte EA, Morgan M, Abrams M. Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry. 2002; 159(1):122-9. PMID: 11772700.
17. Furmark T, Appel L, Henningsson S, Ahs F, Faria V, Linnman C, et al. A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety. J Neurosci. 2008; 28(49):13066-74. doi: 10.1523/JNEUROSCI.2534-08.2008 PMID: 19052197.
18. Petrovic P, Dietrich T, Fransson P, Andersson J, Carlsson K, Ingvar M. Placebo in emotional processing - induced expectations of anxiety relief activate a generalized modulatory network. Neuron. 2005; 46(6):957-69. doi: 10.1016/j.neuron.2005.05.023 PMID: 15953423.
19. Bingel U, Lorenz J, Schoell E, Weiller C, Buchel C. Mechanisms of placebo analgesia: rACC recruitment of a subcortical antinociceptive network. Pain. 2006; 120(1-2):8-15. doi: 10.1016/j.pain.2005.08. 027 PMID: 16364549.
20. Eippert F, Finsterbusch J, Bingel U, Buchel C. Direct Evidence for Spinal Cord Involvement in Placebo Analgesia. Science. 2009; 326(5951):404-. doi: 10.1126/science.1180142 PMID: 19833962
21. Matre D, Casey KL, Knardahl S. Placebo-induced changes in spinal cord pain processing. J Neurosci. 2006; 26(2):559-63. doi: 10.1523/JNEUROSCI.4218-05.2006 PMID: 16407554.
22. Jensen KB, Kaptchuk TJ, Kirsch I, Raicek J, Lindstrom KM, Berna C, et al. Nonconscious activation of placebo and nocebo pain responses. Proc Natl Acad Sci U S A. 2012; 109(39):15959-64. doi: 10.1073/pnas.1202056109 PMID: 23019380; PubMed Central PMCID: PMC3465419.
23. Jensen KB, Kaptchuk TJ, Chen X, Kirsch I, Ingvar M, Gollub RL, et al. A Neural Mechanism for Nonconscious Activation of Conditioned Placebo and Nocebo Responses. Cereb Cortex. 2014. doi: 10.1093/cercor/bhu275 PMID: 25452576.
24. Brockwell SE, Gordon IR. A comparison of statistical methods for meta-analysis. Stat Med. 2001; 20 (6):825-40. doi: 10.1002/sim.650 PMID: 11252006.
25. Bennett FC, McClelland S, Kriegsmann EA, Andrus LB, Sells CJ. Vitamin and mineral supplementation in Down's syndrome. Pediatrics. 1983; 72(5):707-13. PMID: 6226926.
26. Berry-Kravis E, Krause SE, Block SS, Guter S, Wuu J, Leurgans S, et al. Effect of CX516, an AMPAmodulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. J Child Adolesc Psychopharmacol. 2006; 16(5):525-40. doi: 10.1089/cap.2006.16.525 PMID: 17069542.
27. Berry-Kravis EM, Hessl D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen K, et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med. 2012; 4(152):152ra27. doi: 10.1126/scitranslmed. 3004214 PMID: 22993294.
28. Blehaut H, Mircher C, Ravel A, Conte M, de Portzamparc V, Poret G, et al. Effect of leucovorin (folinic acid) on the developmental quotient of children with Down's syndrome (trisomy 21) and influence of thyroid status. PLoS One. 2010; 5(1):e8394. doi: 10.1371/journal.pone.0008394 PMID: 20084109; PubMed Central PMCID: PMC2799517.
29. Boada R, Hutaff-Lee C, Schrader A, Weitzenkamp D, Benke TA, Goldson EJ, et al. Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial. Transl Psychiatry. 2012; 2:e141. doi: 10.1038/tp.2012.66 PMID: 22806212; PubMed Central PMCID: PMC3410988.
30. Ellis JM, Tan HK, Gilbert RE, Muller DP, Henley W, Moy R, et al. Supplementation with antioxidants and folinic acid for children with Down's syndrome: randomised controlled trial. BMJ. 2008; 336 (7644):594-7. doi: 10.1136/bmj.39465.544028.AE PMID: 18296460; PubMed Central PMCID: PMC2267988.
31. Hagerman RJ, Jackson AW, Levitas A, Braden M, McBogg P, Kemper M, et al. Oral folic acid versus placebo in the treatment of males with the fragile X syndrome. Am J Med Genet. 1986; 23(1-2):241-62. PMID: 3513567.
32. Hanney M, Prasher V, Williams N, Jones EL, Aarsland D, Corbett A, et al. Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebocontrolled trial. Lancet. 2012; 379(9815):528-36. doi: 10.1016/S0140-6736(11)61676-0 PMID: 22236802.
33. Haqq AM, Stadler DD, Jackson RH, Rosenfeld RG, Purnell JQ, LaFranchi SH. Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi syndrome. J Clin Endocrinol Metab. 2003; 88(5):2206-12. doi: 10.1210/jc.2002-021536 PMID: 12727976.
34. Johnson N, Fahey C, Chicoine B, Chong G, Gitelman D. Effects of donepezil on cognitive functioning in Down syndrome. Am J Ment Retard. 2003; 108(6):367-72. doi: 10.1352/0895-8017(2003)108<367: EODOCF>2.0.CO;2 PMID: 14561111.
35. Kishnani PS, Sommer BR, Handen BL, Seltzer B, Capone GT, Spiridigliozzi GA, et al. The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome. Am J Med Genet A. 2009; 149A(8):1641-54. doi: 10.1002/ajmg.a.32953 PMID: 19606472.
36. Kishnani PS, Heller JH, Spiridigliozzi GA, Lott I, Escobar L, Richardson S, et al. Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10-17. Am J Med Genet A. 2010; 152A (12):3028-35. doi: 10.1002/ajmg.a.33730 PMID: 21108390.
37. Kondoh T, Kanno A, Itoh H, Nakashima M, Honda R, Kojima M, et al. Donepezil significantly improves abilities in daily lives of female Down syndrome patients with severe cognitive impairment: a 24-week randomized, double-blind, placebo-controlled trial. Int J Psychiatry Med. 2011; 41(1):71-89. PMID: 21495523.
38. Leigh MJ, Nguyen DV, Mu Y, Winarni TI, Schneider A, Chechi T, et al. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome. J Dev Behav Pediatr. 2013; 34(3):147-55. doi: 10.1097/DBP.0b013e318287cd17 PMID: 23572165; PubMed Central PMCID: PMC3706260.
39. Prasher VP, Huxley A, Haque MS, Down syndrome Ageing Study G. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease - pilot study. Int J Geriatr Psychiatry. 2002; 17(3):270-8. PMID: 11921156.
40. Pueschel SM, Reed RB, Cronk CE, Goldstein BI. 5-hydroxytryptophan and pyridoxine. Their effects in young children with Down's syndrome. Am J Dis Child. 1980; 134(9):838-44. PMID: 6447999.
41. Sahu JK, Gulati S, Sapra S, Arya R, Chauhan S, Chowdhury MR, et al. Effectiveness and safety of donepezil in boys with fragile x syndrome: a double-blind, randomized, controlled pilot study. J Child Neurol. 2013; 28(5):570-5. doi: 10.1177/0883073812449381 PMID: 22752489.
42. Selikowitz M, Sunman J, Pendergast A, Wright S. Fenfluramine in Prader-Willi syndrome: a double blind, placebo controlled trial. Arch Dis Child. 1990; 65(1):112-4. PMID: 2405783; PubMed Central PMCID: PMC1792401.
43. Smith GF, Spiker D, Peterson CP, Cicchetti D, Justine P. Use of megadoses of vitamins with minerals in Down syndrome. J Pediatr. 1984; 105(2):228-34. PMID: 6235336.
44. Torrioli MG, Vernacotola S, Peruzzi L, Tabolacci E, Mila M, Militerni R, et al. A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. Am J Med Genet A. 2008; 146A(7):803-12. doi: 10.1002/ajmg.a.32268 PMID: 18286595.
45. van Trotsenburg AS, Vulsma T, van Rozenburg-Marres SL, van Baar AL, Ridder JC, Heymans HS, et al. The effect of thyroxine treatment started in the neonatal period on development and growth of two-year-old Down syndrome children: a randomized clinical trial. J Clin Endocrinol Metab. 2005; 90 (6):3304-11. doi: 10.1210/jc.2005-0130 PMID: 15755847.
46. Weathers C. Effects of nutritional supplementation on IQ and certain other variables associated with Down syndrome. Am J Ment Defic. 1983; 88(2):214-7. PMID: 6227244.
47. Sauro MD, Greenberg RP. Endogenous opiates and the placebo effect: a meta-analytic review. J Psychosom Res. 2005; 58(2):115-20. doi: 10.1016/j.jpsychores.2004.07.001 PMID: 15820838.
48. Zhang W, Robertson J, Jones AC, Dieppe PA, Doherty M. The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis. 2008; 67(12):1716-23. doi: 10.1136/ard.2008.092015 PMID: 18541604.
49. Walach HaM, C. Is the placebo effect dependent on time? A meta-analysis. in Kirsch I, editor. Washington, D.C.: American Psychological Association; 1999. 321-32 p.
50. Weimer K, Gulewitsch MD, Schlarb AA, Schwille-Kiuntke J, Klosterhalfen S, Enck P. Placebo effects in children: a review. Pediatr Res. 2013; 74(1):96-102. doi: 10.1038/pr.2013.66 PMID: 23598811.
51. Rief W, Nestoriuc Y, Weiss S, Welzel E, Barsky AJ, Hofmann SG. Meta-analysis of the placebo response in antidepressant trials. J Affect Disord. 2009; 118(1-3):1-8. doi: 10.1016/j.jad.2009.01.029 PMID: 19246102.
52. Patel SM, Stason WB, Legedza A, Ock SM, Kaptchuk TJ, Conboy L, et al. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil. 2005; 17(3):332-40. doi: 10.1111/j. 1365-2982.2005.00650.x PMID: 15916620.
53. Fulda S, Wetter TC. Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies. Brain. 2008; 131(Pt 4):902-17. doi: 10.1093/brain/awm244 PMID: 17932100.
54. Rutherford BR, Pott E, Tandler JM, Wall MM, Roose SP, Lieberman JA. Placebo response in antipsychotic clinical trials: a meta-analysis. JAMA Psychiatry. 2014; 71(12):1409-21. doi: 10.1001/jamapsychiatry.2014.1319 PMID: 25321611; PubMed Central PMCID: PMC4256120.
55. Finniss DG, Kaptchuk TJ, Miller F, Benedetti F. Biological, clinical, and ethical advances of placebo effects. Lancet. 2010; 375(9715):686-95. doi: 10.1016/S0140-6736(09)61706-2 PMID: 20171404; PubMed Central PMCID: PMC2832199.
56. Price DD, Finniss DG, Benedetti F. A comprehensive review of the placebo effect: recent advances and current thought. Annu Rev Psychol. 2008; 59:565-90. doi: 10.1146/annurev.psych.59.113006. 095941 PMID: 17550344.
57. Klinger R, Soost S, Flor H, Worm M. Classical conditioning and expectancy in placebo hypoalgesia: a randomized controlled study in patients with atopic dermatitis and persons with healthy skin. Pain. 2007; 128(1-2):31-9. doi: 10.1016/j.pain.2006.08.025 PMID: 17030095.
58. Conzemius MG, Evans RB. Caregiver placebo effect for dogs with lameness from osteoarthritis. J Am Vet Med Assoc. 2012; 241(10):1314-9. doi: 10.2460/javma.241.10.1314 PMID: 23113523.
59. Talbot WA, Pinchbeck GL, Knottenbelt DC, Graham H, McKane SA. A randomised, blinded, crossover study to assess the efficacy of a feed supplement in alleviating the clinical signs of headshaking in 32 horses. Equine Vet J. 2013; 45(3):293-7. doi: 10.1111/j.2042-3306.2012.00618.x PMID: 22994634.
60. Grelotti DJ, Kaptchuk TJ. Placebo by proxy. BMJ. 2011; 343:d4345. doi: 10.1136/bmj.d4345 PMID: 21835868; PubMed Central PMCID: PMC3230083.
61. Whalley B, Hyland ME. Placebo by proxy: the effect of parents' beliefs on therapy for children's temper tantrums. J Behav Med. 2013; 36(4):341-6. doi: 10.1007/s10865-012-9429-x PMID: 22580966.
62. Sandler AD, Bodfish JW. Placebo effects in autism: lessons from secretin. J Dev Behav Pediatr. 2000; 21(5):347-50. PMID: 11064962.
63. Williams KW, Wray JJ, Wheeler DM. Intravenous secretin for autism spectrum disorder. Cochrane Database Syst Rev. 2005;(3: ):CD003495. doi: 10.1002/14651858.CD003495.pub2 PMID: 16034901.
64. des Portes V. X-linked mental deficiency. Handb Clin Neurol. 2013; 111:297-306. doi: 10.1016/B978-0-444-52891-9.00035-X PMID: 23622180.
65. Frankland PW, Wang Y, Rosner B, Shimizu T, Balleine BW, Dykens EM, et al. Sensorimotor gating abnormalities in young males with fragile X syndrome and Fmr1-knockout mice. Mol Psychiatry. 2004; 9(4):417-25. doi: 10.1038/sj.mp.4001432 PMID: 14981523.
66. Hessl D, Berry-Kravis E, Cordeiro L, Yuhas J, Ornitz EM, Campbell A, et al. Prepulse inhibition in fragile X syndrome: feasibility, reliability, and implications for treatment. Am J Med Genet B Neuropsychiatr Genet. 2009; 150B(4):545-53. doi: 10.1002/ajmg.b.30858 PMID: 18785205; PubMed Central PMCID: PMC2693303.
67. Benedetti F, Arduino C, Costa S, Vighetti S, Tarenzi L, Rainero I, et al. Loss of expectation-related mechanisms in Alzheimer's disease makes analgesic therapies less effective. Pain. 2006; 121(1-2):133-44. doi: 10.1016/j.pain.2005.12.016 PMID: 16473462.
68. Khan A, Redding N, Brown WA. The persistence of the placebo response in antidepressant clinical trials. J Psychiatr Res. 2008; 42(10):791-6. doi: 10.1016/j.jpsychires.2007.10.004 PMID: 18036616.
69. Rana JS, Mannam A, Donnell-Fink L,Gervino EV, Sellke FW, Laham RJ. Longevity of the placebo effect in the therapeutic angiogenesis and laser myocardial revascularization trials in patients with coronary heart disease. Am J Cardiol. 2005; 95(12):1456-9. doi: 10.1016/j.amjcard.2005.02.013 PMID: 15950570.
70. Kasari C, Freeman SF, Bass W. Empathy and response to distress in children with Down syndrome. J Child Psychol Psychiatry. 2003; 44(3):424-31. PMID: 12635971.
71. Hagerman RJ, Hagerman PJ. The fragile X premutation: into the phenotypic fold. Curr Opin Genet Dev. 2002; 12(3):278-83. PMID: 12076670.
72. Lightbody AA, Reiss AL. Gene, brain, and behavior relationships in fragile X syndrome: evidence from neuroimaging studies. Dev Disabil Res Rev. 2009; 15(4):343-52. doi: 10.1002/ddrr.77 PMID: 20014368; PubMed Central PMCID: PMC4354896.
73. Grieco J, Pulsifer M, Seligsohn K, Skotko B, Schwartz A. Down syndrome: Cognitive and behavioral functioning across the lifespan. Am J Med Genet C Semin Med Genet. 2015; 169(2):135-49. doi: 10. 1002/ajmg.c.31439 PMID: 25989505.
74. Finestack LH, Richmond EK, Abbeduto L. Language Development in Individuals with Fragile X Syndrome. Top Lang Disord. 2009; 29(2):133-48. PMID: 20396595; PubMed Central PMCID: PMC2854517.
75. Hooper SR, Hatton D, Sideris J, Sullivan K, Hammer J, Schaaf J, et al. Executive functions in young males with fragile X syndrome in comparison to mental age-matched controls: baseline findings from a longitudinal study. Neuropsychology. 2008; 22(1):36-47. doi: 10.1037/0894-4105.22.1.36 PMID: 18211154.
76. Lott IT, Dierssen M. Cognitive deficits and associated neurological complications in individuals with Down's syndrome. Lancet Neurol. 2010; 9(6):623-33. doi: 10.1016/S1474-4422(10)70112-5 PMID: 20494326.
77. Vicari S, Pontillo M, Armando M. Neurodevelopmental and psychiatric issues in Down's syndrome: assessment and intervention. Psychiatr Genet. 2013; 23(3):95-107. doi: 10.1097/YPG. 0b013e32835fe426 PMID: 23492931.
78. Rothner AD, Wasiewski W, Winner P, Lewis D, Stankowski J. Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents. Headache. 2006; 46(1):101-9. doi: 10.1111/j.1526-4610.2006.00313.x PMID: 16412157.
79. Faria V, Linnman C, Lebel A, Borsook D. Harnessing the placebo effect in pediatric migraine clinic. J Pediatr. 2014; 165(4):659-65. doi: 10.1016/j.jpeds.2014.06.040 PMID: 25063720; PubMed Central PMCID: PMC4358740.
80. El-Chammas K, Keyes J, Thompson N, Vijayakumar J, Becher D, Jackson JL. Pharmacologic treatment of pediatric headaches: a meta-analysis. JAMA Pediatr. 2013; 167(3):250-8. doi: 10.1001/jamapediatrics.2013.508 PMID: 23358935.
81. Rheims S, Cucherat M, Arzimanoglou A, Ryvlin P. Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy. PLoS Med. 2008; 5(8): e166. doi: 10.1371/journal.pmed.0050166 PMID: 18700812; PubMed Central PMCID: PMC2504483.
82. Berry-Kravis E, Hessl D, Abbeduto L, Reiss AL, Beckel-Mitchener A, Urv TK, et al. Outcome measures for clinical trials in fragile X syndrome. J Dev Behav Pediatr. 2013; 34(7):508-22. doi: 10.1097/DBP. 0b013e31829d1f20 PMID: 24042082; PubMed Central PMCID: PMC3784007.
83. Hagerman R, Lauterborn J, Au J, Berry-Kravis E. Fragile X syndrome and targeted treatment trials. Results Probl Cell Differ. 2012; 54:297-335. doi: 10.1007/978-3-642-21649-7-17 PMID: 22009360; PubMed Central PMCID: PMC4114775.
84. Jacquemont S, Curie A, des Portes V, TorrioliMG, Berry-Kravis E, Hagerman RJ, et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to themGluR5 antagonist AFQ056. Sci TranslMed. 2011; 3(64):64ra1. doi: 10.1126/scitranslmed.3001708 PMID: 21209411.